Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Great Buying Opportunity In Pozen Shares

On July 28, 2014, Horizon Pharma, Inc. (NASDAQ:HZNP) filed a Form 8-K with the SEC disclosing that two pharmacy benefit managers, CVS Caremark (NYSE:CVS) and Express Scripts, Inc. (NASDAQ:ESRX), expect to announce DUEXIS® and VIMOVO® will no longer be on their formularies and will be placed on their exclusion lists effective January 1, 2015. In the first quarter 2014, DUEXIS® and VIMOVO® accounted for 92% of Horizon's net product sales. Horizon estimates 20-30% of its DUEXIS® and VIMOVO® prescriptions could be at risk by being excluded from the these formularies.

Exclusion from formulary listing means patients will have to cover the full cost of the drug out-of-pocket. One month of DUEXIS®, a combination ibuprofen...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details